Inventor · disambiguated record
Jayaprakash K. Nair
Also filed as: NAIR JAYAPRAKASH · NAIR JAYAPRAKASH K
41 granted patents·36 pending applications·429 citations·filing 2012–2025
98Inventor score
Top patents by PatentIndex Score
77 records- 0199US10806791B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·14 cites·12 claims
- 0299US9682139B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Jun 20, 2017·46 cites·20 claims
- 0399US9352048B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·112 cites·20 claims
- 0498US11110174B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 7, 2021·10 cites·20 claims
- 0598US9867882B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 16, 2018·33 cites·29 claims
- 0697US9764036B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2015·Granted Sep 19, 2017·19 cites·22 claims
- 0797US9682922B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 20, 2017·39 cites·18 claims
- 0897US9370581B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Jun 21, 2016·24 cites·20 claims
- 0996US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 1096US10117941B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Nov 6, 2018·12 cites·14 claims
- 1196US9370582B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Jun 21, 2016·23 cites·20 claims
- 1295US10821186B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2018·Granted Nov 3, 2020·4 cites·24 claims
- 1394US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
- 1493US11666653B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jun 6, 2023·1 cites·22 claims
- 1593US10086081B2Carbohydrate conjugated RNA agents and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Oct 2, 2018·11 cites·10 claims
- 1692US12364762B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 22, 2025·0 cites·14 claims
- 1792US12350338B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 8, 2025·0 cites·14 claims
- 1892US12343398B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 1, 2025·0 cites·30 claims
- 1992US12239709B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Mar 4, 2025·0 cites·28 claims
- 2091US11420931B2Lipid containing formulationsARBUTUS BIOPHARMA CORP·Filed 2019·Granted Aug 23, 2022·2 cites·20 claims
- 2191US9814777B2Targeting lipidsARBUTUS BIOPHARMA CORP·Filed 2013·Granted Nov 14, 2017·8 cites·11 claims
- 2291US9566340B2Monomers and oligonucleotides comprising cycloaddition adduct(s)ALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 14, 2017·11 cites·12 claims
- 2390US9999673B2PEGylated lipids and their use for drug deliveryRAJEEV KALLANTHOTTATHIL G·Filed 2012·Granted Jun 19, 2018·18 cites·29 claims
- 2488US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
- 2588US2023381319A1Novel lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2023·Application pending·0 cites
- 2686US9701623B2Di-aliphatic substituted pegylated lipidsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 11, 2017·5 cites·40 claims
- 2785US11597932B2Chirally-enriched double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·3 cites·24 claims
- 2885US10808246B2Oligonucleotide-ligand conjugates and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Oct 20, 2020·6 cites·9 claims
- 2985US2025236871A1Multi-targeted single entity conjugatesALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3085US2024252653A1Carbohydrate conjugated rna agents and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3185US2025207131A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3283US12005074B2Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·0 cites·28 claims
- 3383US2025043279A1SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3483US2024358738A1Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3582US11034957B2Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·1 cites·30 claims
- 3682US2023174459A1Lipid containing formulationsARBUTUS BIOPHARMA CORP·Filed 2022·Application pending·0 cites
- 3782US2025075208A1Oligonucleotide-ligand conjugates and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3881US12059468B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 13, 2024·0 cites·29 claims
- 3979US12275938B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 15, 2025·0 cites·38 claims
- 4079US11944687B2Carbohydrate conjugate RNA agents and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 2, 2024·0 cites·4 claims
- 4178US2021162053A1Novel lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2020·Application pending·0 cites
- 4276US2024200061A1TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4376US2023256001A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4474US12221607B2Multi-targeted single entity conjugatesALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 11, 2025·0 cites·24 claims
- 4574US10835612B2Lipids and compositions for the delivery of therapeuticsARBUTUS BIOPHARMA CORP·Filed 2017·Granted Nov 17, 2020·0 cites·17 claims
- 4672US12247203B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 11, 2025·0 cites·20 claims
- 4772US12173288B2Oligonucleotide-ligand conjugates and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Dec 24, 2024·0 cites·6 claims
- 4870US12397013B2Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Aug 26, 2025·0 cites·66 claims
- 4970US2023122244A1Chirally-enriched double-stranded rna agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5069US2019099493A1Targeting LipidsARBUTUS BIOPHARMA CORP·Filed 2017·Application pending·0 cites
Showing the top 50 of 77 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jayaprakash K. Nair files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →